Safety and Efficacy of AS-3201 in the Treatment of Diabetic Sensorimotor Polyneuropathy
Status:
Completed
Trial end date:
2006-09-01
Target enrollment:
Participant gender:
Summary
This is a safety and efficacy trial of ranirestat(AS-3201) which is an aldose reductase
inhibitor in patients with diabetic sensorimotor polyneuropathy.